Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
23 8월 2023 - 5:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
today announced the appointment of M. Christina Yi to Chief
Technology Officer effective August 21, 2023. Ms. Yi has more than
25 years of biopharmaceuticals leadership experience, including
manufacturing, quality, and supply chain. She succeeds Wayne
Gombotz, Ph.D., who will retire in August.
“Christina is an accomplished industry leader and will be a key
addition to our executive team as we prepare for a broad
development plan for povetacicept. Her expertise and leadership
will be important to Alpine as we continue to advance our pipeline
to provide meaningful new therapeutic options for patients living
with autoimmune and inflammatory diseases,” said Mitchell Gold,
Executive Chairman and Chief Executive Officer. “We thank Wayne for
his significant contributions and leadership during his tenure at
Alpine. He has been a great member of the Alpine executive team as
we moved several of our platform programs into the clinic under his
leadership. We appreciate his dedication to Alpine over the last
five years and wish him well during his retirement.”
Ms. Yi joins Alpine from Provention Bio, Inc., a Sanofi company,
where she served as Chief Operations Officer and played a critical
role in the achievement of U.S. Food and Drug Administration
approval and subsequent commercial launch of Tzield™
(teplizumab-mzwv), a first-in-class therapy for type 1 diabetes.
Prior to that, she served as Chief Operating Officer at Vaxxinity
and Chief Operations Officer at Dendreon Pharmaceuticals LLC.
Earlier in her career, she held roles of increasing responsibility
at Amgen in Quality for three commercially successful products. She
received a B.S. in cell and molecular biology from the University
of Washington, Seattle.
“I have been closely following the Alpine story and I am excited
to be part of the company as they prepare to pursue a broad
development plan for povetacicept across a number of auto-antibody
mediated inflammatory diseases,” said Christina Yi.
In conjunction with her employment, effective August 21, 2023,
Ms. Yi has been granted an option to purchase 185,000 shares of
common stock. The option will vest with respect to 25% of the
shares underlying the option on the one-year anniversary of her
employment start date with the Company; the remaining 75% of the
shares underlying the option will vest in equal monthly
installments over the 36-month period following the one-year
anniversary of Ms. Yi's employment start date, subject to her
continued service to Alpine through each relevant vesting date.
In addition, pursuant to the terms of Alpine’s change of control
and severance policy, if there is a change of control and, upon or
during the 12 months after the change of control, Ms. Yi's
employment is terminated either (i) by Alpine without cause or (ii)
by Ms. Yi for good reason, the option will become fully vested and
exercisable. The option has a ten-year term and an exercise price
of $13.44, equal to the per share closing price of Alpine’s common
stock as reported by Nasdaq on August 21, 2023. The stock options
were granted outside Alpine’s 2018 Equity Incentive Plan as an
inducement material to Ms. Yi entering into employment with Alpine
in accordance with Nasdaq Listing Rule 5635(c)(4). The terms and
conditions of the option are generally consistent with those in
Alpine’s 2018 Equity Incentive Plan.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on
Twitter and LinkedIn.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology, potential therapies and product candidates,
including those regarding our future development plans.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions and include words such as “may,” “will,” “should,”
“would,” “expect,” “plan,” “intend,” and other similar expressions,
among others. These forward-looking statements are based on current
assumptions that involve risks, uncertainties, and other factors
that may cause actual results, events, or developments to be
materially different from those expressed or implied by such
forward-looking statements. These risks and uncertainties, many of
which are beyond our control, include, but are not limited to:
clinical trials may not demonstrate safety and efficacy of any of
our product candidates; our ongoing discovery and preclinical
efforts may not yield additional product candidates; our
discovery-stage and preclinical programs may not advance into the
clinic or result in approved products; any of our product
candidates may fail in development, may not receive required
regulatory approvals, or may be delayed to a point where they are
not commercially viable; we may not achieve additional milestones
in our proprietary or partnered programs; the impact of
competition; adverse conditions in the general domestic and global
economic markets; the impact of pandemics, or other related health
crises on our business, research and clinical development plans and
timelines and results of operations, including the impact on our
clinical trial sites, collaborators, and contractors who act for or
on our behalf, may be more severe and prolonged than currently
anticipated; as well as the other risks identified in our filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and we undertake no
obligation to update forward-looking statements, and readers are
cautioned not to place undue reliance on such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230822041212/en/
Media and Investor Relations Contact: Temre Johnson
Alpine Immune Sciences, Inc. ir@alpineimmunesciences.com
media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024